TAVR is safe for patients with large aortic annuli—heart failure remains a concern

August 20, 2026 - 20:06

New data suggest that transcatheter aortic valve replacement (TAVR) is a safe option for patients with large or extra-large aortic annuli, though the procedure does not eliminate the ongoing threat of heart failure in this group. The findings add nuance to the ongoing debate about which patients benefit most from TAVR versus surgical aortic valve replacement (SAVR).

The study, presented at a major cardiology conference, looked at patients with anatomically challenging aortic roots. Researchers found that TAVR achieved good hemodynamic results and low rates of procedural complications, even in those with very large annuli. This is important because oversized anatomies were once considered a relative contraindication for the catheter-based approach.

However, the follow-up data showed a sobering trend. Despite successful valve deployment and improved valve function, a significant number of patients still experienced heart failure hospitalizations within the first year. The risk was particularly noticeable in patients with pre-existing left ventricular dysfunction or significant calcification of the outflow tract. This suggests that while the valve itself performs well, the underlying heart muscle disease may continue to progress.

The authors stress that patient selection remains critical. A large annulus alone should not automatically push a patient toward surgery. Instead, the heart team must weigh the full clinical picture, including ventricular function, frailty, and the presence of other valvular lesions. In some cases, SAVR might still offer better long-term outcomes, particularly for younger patients with low surgical risk.

For now, the message is clear: TAVR is a viable and safe tool for large annuli, but it is not a cure-all. Close post-procedure monitoring for heart failure symptoms is essential, and clinicians should not assume that a good valve result translates into a symptom-free life. The decision between TAVR and SAVR should remain a shared, individualized discussion between the patient and the heart team, based on more than just annular dimensions.